Ozagrel (OKY-046) 是一种口服有效的高选择性血栓素A2 (TXA2) 合成酶抑制剂 (IC50=11 nM)。它通过抑制TXA2生成并增加前列环素(PGI2)产生,从而发挥抗血小板、扩张血管和抗炎作用,可用于缺血性卒中、哮喘及血栓栓塞性疾病的研究。
|
英文别名 (English Synonym) |
Ozagrel |
|
中文名称 (Chinese Name) |
奥扎格雷 |
|
靶点 (Target) |
Factor Xa |
|
通路 (Pathway) |
Protease/Metabolic Enzyme |
|
CAS号 (CAS NO.) |
82571-53-7 |
|
分子式 (Formula) |
C13H12N2O2 |
|
分子量 (Molecular Weight) |
228.25 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Saito MS, Lourenço AL, Dias LR, Freitas AC, Vitorino MI, Albuquerque MG, Rodrigues CR, Cabral LM, Dias EP, Castro HC, Satlher PC. Antiplatelet pyrazolopyridines derivatives: pharmacological, biochemical and toxicological characterization. J Enzyme Inhib Med Chem. 2016 Dec,31(6):1591-601. doi: 10.3109/14756366.2016.1158712. Epub 2016 Mar 22. PMID: 27000933.[2]Bhatia P, Singh N. Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia. Fundam Clin Pharmacol. 2021 Aug,35(4):650-666. doi: 10.1111/fcp.12610. Epub 2020 Dec 5. PMID: 33020931.
